Mutual Funds Commodities Research Tax Planning IPO Our Team Contact Us  

| More

Pharmaceuticals & Healthcare - India growth to recover; US to remain stable - ICICI Securities

Posted On: 2021-01-07 06:44:26 (Time Zone: Arizona, USA)

We expect pharma and healthcare companies under our coverage to report moderate growth during the quarter ended Dec'20. We expect easing of lockdown to support some recovery in acute portfolio and injectable products. US revenues may witness marginal growth sequentially led by improvement in volumes of injectables, specialty portfolio and new launches. We estimate India business to grow in high single digit as seen in secondary sales data. We forecast the EBITDA margin of covered companies at ~22% (+130bps YoY) led by revenue growth and cost control measures. Hospitals and diagnostic centres can report significant recovery QoQ with rise in occupancy levels and pathology test volumes. Overall, we expect our coverage universe to report ~8% revenue growth.

- India secondary sales: The Indian pharma market witnessed a growth of 6.4% in value terms for Q3FY21 (source: AWACS). Volumes declined 1.9%, while prices and new introductions grew 4.9% and 3.4%, respectively. We expect primary sales YoY growth for under coverage companies similar or faster than the industry.

- US generics: US sales may grow ~2% QoQ in Q3FY21. Dr Reddy's and Glenmark will have largely flattish sales. We expect Lupin, Alkem, Alembic and Strides to show QoQ growth in US sales led by injectables, specialty products and new launches. Other companies would remain largely flattish in a stable environment.

- Companies to watch: We expect relatively better results from: 1) Aurobindo with new product approvals and stable pricing; 2) Dr Reddy's & Biocon with new product launches in the US; 3) Sun & Alembic with traction in existing and specialty products and 4) Divis lab led by strong demand for APIs from India. Healthcare companies would report decent recovery in non-COVID business as lockdown restrictions have been eased.

- Key factors to watch out during management commentary: i) Growth outlook in India for the industry and respective companies, ii) update on restart of USFDA inspections, iii) price scenario in base US business and traction in specialty products, iv) growth in emerging markets with demand outlook and v) sustainability of recovery in diagnostics and hospitals.

Source: Equity Bulls

Click here to send ur comments or to

Disclaimer:The article above is a gist / extract of the original report prepared by the research firm / brokerage firm. This article is not to be considered as an offer to sell or a solicitation to buy any securities. This article is meant for general information only., its employees or owners or the research firms, its employees or owners won't be responsible for any liability that may arise from information, errors or omissions in these articles. or its employees or owners / the research firms or its employees or clients or owners may from time to time hold positions in securities referred in this article. For detailed research reports, please contact the concerned research firm directly.

Other Headlines:

Union Budget 2021-22 - Preview Report - YES SECURITIES

Alembic Pharma (Q3 FY21) - 'First signs of sartans weakness' - YES Securities

CSB Bank Q3 Earnings Call - Key Takeaways - YES Securities

ICICI Lombard - Q3FY21 Result Report - YES Securities

Gateway Distriparks - Q3FY21 - Multiple triggers at play - ICICI Securities

Prince Pipes and Fittings - Improving governance; rerating inevitable - ICICI Securities

CEAT - Margins resilient due to healthy replacement mix - ICICI Securities

Hatsun Agro Products - Commencement of three plants and lower tax rate to boost return ratios in FY22 and beyond - ICICI Securities

Alembic Pharmaceuticals - India recovers, US sees pressure - ICICI Securities

Q3FY21 Result update - MindTree Ltd - ICICI Direct

Q3FY21 Company update - Shoppers Stop - ICICI Direct

IPO - Indigo Paints Ltd - ICICI Direct

Larsen & Toubro Infotech Ltd - Q3FY21 First Cut - ICICI Direct

Tata Communications - Q3FY21 First Cut - ICICI Direct

Maintain ADD on Mindtree - Into another operating orbit - HDFC Securities

NBFCs Q3FY21 Results Preview - Micro headwinds > Macro tailwinds - HDFC Securities

Mindtree - Margin beat and raise cycle seems to be over! - ICICI Securities

Shoppers Stop - Focusing on omni-channel growth - ICICI Securities

Piramal Enterprises - Strategic synergies, optional value to follow DHFL's buyout - ICICI Securities

Motherson Sumi Systems - Focus remains on growth and cost efficiency - ICICI Securities

Metropolis Healthcare - Acquires Hitech Diagnostics in South India - ICICI Securities

Nifty PE shifting orbits - ICICI Direct

Rallis India Ltd - Q3FY21 First Cut - ICICI Direct

Q3FY21 Company update - GTPL Hathway - ICICI Direct

Q3FY21 Result update - HDFC Bank - ICICI Direct

Q3FY21 Result Update - PVR Ltd - ICICI Direct

Q3FY21 Result update - HCL Technologies - ICICI Direct

Maintain BUY on HCL Technologies - Mode-2, 3 driven momentum - HDFC Securities

HDFC Bank Q3FY21 Results - Concall Highlights and Views of YES SECURITIES

HDFC Bank Q3 FY21 - 'Stellar Show' - Retain BUY and raise 12m PT to Rs1870 - YES Securities

IPO Review - Indian Railway Finance Corporation (IRFC) - ICICI Direct

HCL Technologies - Q3FY21 First Cut - ICICI Direct

Logistics Sector Update - Indian Railways - getting aggressive - HDFC Securities

Indigo Paints - IPO view - YES SECURITIES

Infosys - Near-term margins will likely come under pressure - ICICI Securities

CESC - 7% dividend yield + higher ESG rating - ICICI Securities

South Indian Bank - Unveils vision 2024; targets RoA / RoE of 1% / 13% by 2024 - ICICI Securities

Maintain BUY on Infosys - Growth certainty on explosive deal wins - HDFC Securities

Maintain ADD on Wipro - Growth acceleration - HDFC Securities

Consumer Durables - Q3FY21 Results Preview - HDFC Securities

Q3FY21 Company Update - Filatex India - ICICI Direct

Q3FY21 Result Update - Wipro Ltd - ICICI Direct

Q3FY21 Result Update - CESC - ICICI Direct

Monthly Inflation - December 2020 - ICICI Direct

Q3FY21 Result Update - Infosys - ICICI Direct

Banks Q3FY21 Results Preview - Scope for optimism beyond a tepid 3Q - HDFC Securities

Consumer Discretionary Companies - Q3FY21 Results Preview Report - HDFC Securities

Pharma Sector Update - Ample catalysts to sustain luster - HDFC Securities

Suman Chowdhury, Chief Analytical Officer, Acuité Ratings & Research on IIP data

Infosys - Q3FY21 First Cut - ICICI Direct

Website Created & Maintained by : Chennai Scripts
West Mambalam, Chennai - 600 033,
Tamil Nadu, India

disclaimer copyright © 2005 - 2020